{"id":240824,"date":"2026-07-14T12:08:52","date_gmt":"2026-07-14T17:08:52","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/07\/an-experimental-alzheimers-drug-shows-promise-targeting-a-different-brain-protein-new-study-shows"},"modified":"2026-07-14T12:08:52","modified_gmt":"2026-07-14T17:08:52","slug":"an-experimental-alzheimers-drug-shows-promise-targeting-a-different-brain-protein-new-study-shows","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/07\/an-experimental-alzheimers-drug-shows-promise-targeting-a-different-brain-protein-new-study-shows","title":{"rendered":"An experimental Alzheimer\u2019s drug shows promise targeting a different brain protein, new study shows"},"content":{"rendered":"

<\/a><\/p>\n

WASHINGTON (AP) \u2014 An experimental drug might help slow early Alzheimer\u2019s disease<\/a> in a markedly different way than today\u2019s treatments<\/a> \u2014 by lowering levels of a brain protein called tau, researchers reported Tuesday.<\/p>\n

Tau is one part of a toxic duo<\/a> fueling Alzheimer\u2019s but prior attempts to develop drugs that can target the protein have failed. Two Alzheimer\u2019s drugs, lecanemab and donanemab, try to clear buildup of the better-known amyloid protein<\/a> and can modestly slow cognitive decline.<\/p>\n

The new findings suggest Biogen\u2019s diranersen did more than lower tau levels. The study of about 400 people found signs that it also slowed cognitive decline, in one small subset enough to be comparable to amyloid therapy, according to results presented at the Alzheimer\u2019s Association International Conference in London. Biogen is planning a larger study to try to prove the drug\u2019s benefit.<\/p>\n","protected":false},"excerpt":{"rendered":"

WASHINGTON (AP) \u2014 An experimental drug might help slow early Alzheimer\u2019s disease in a markedly different way than today\u2019s treatments \u2014 by lowering levels of a brain protein called tau, researchers reported Tuesday. Tau is one part of a toxic duo fueling Alzheimer\u2019s but prior attempts to develop drugs that can target the protein have [\u2026]<\/p>\n","protected":false},"author":396,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,47],"tags":[],"class_list":["post-240824","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/240824","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/396"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=240824"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/240824\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=240824"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=240824"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=240824"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}